These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

487 related items for PubMed ID: 23885174

  • 1. The antitumor activity of a doxorubicin loaded, iRGD-modified sterically-stabilized liposome on B16-F10 melanoma cells: in vitro and in vivo evaluation.
    Yu KF, Zhang WQ, Luo LM, Song P, Li D, Du R, Ren W, Huang D, Lu WL, Zhang X, Zhang Q.
    Int J Nanomedicine; 2013; 8():2473-85. PubMed ID: 23885174
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. A comprehensive study of iRGD-modified liposomes with improved chemotherapeutic efficacy on B16 melanoma.
    Dai W, Fan Y, Zhang H, Wang X, Zhang Q, Wang X.
    Drug Deliv; 2015 Jan; 22(1):10-20. PubMed ID: 24735248
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Enhanced intracellular uptake of sterically stabilized liposomal Doxorubicin in vitro resulting in improved antitumor activity in vivo.
    Xiong XB, Huang Y, Lu WL, Zhang H, Zhang X, Zhang Q.
    Pharm Res; 2005 Jun; 22(6):933-9. PubMed ID: 15948037
    [Abstract] [Full Text] [Related]

  • 6. Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic.
    Xiong XB, Huang Y, Lu WL, Zhang X, Zhang H, Nagai T, Zhang Q.
    J Control Release; 2005 Oct 03; 107(2):262-75. PubMed ID: 16125816
    [Abstract] [Full Text] [Related]

  • 7. Does ligand-receptor mediated competitive effect or penetrating effect of iRGD peptide when co-administration with iRGD-modified SSL?
    Zhang WQ, Yu KF, Zhong T, Luo LM, Du R, Ren W, Huang D, Song P, Li D, Zhao Y, Wang C, Zhang X.
    J Drug Target; 2015 Dec 03; 23(10):897-909. PubMed ID: 26087869
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. iNGR-Modified Liposomes for Tumor Vascular Targeting and Tumor Tissue Penetrating Delivery in the Treatment of Glioblastoma.
    Zhou JE, Yu J, Gao L, Sun L, Peng T, Wang J, Zhu J, Lu W, Zhang L, Yan Z, Yu L.
    Mol Pharm; 2017 May 01; 14(5):1811-1820. PubMed ID: 28388081
    [Abstract] [Full Text] [Related]

  • 10. Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide.
    Chen X, Wang X, Wang Y, Yang L, Hu J, Xiao W, Fu A, Cai L, Li X, Ye X, Liu Y, Wu W, Shao X, Mao Y, Wei Y, Chen L.
    J Control Release; 2010 Jul 01; 145(1):17-25. PubMed ID: 20307599
    [Abstract] [Full Text] [Related]

  • 11. Co-delivery of doxorubicin-dihydroartemisinin prodrug/TEPP-46 nano-liposomes for improving antitumor and decreasing cardiotoxicity in B16-F10 tumor-bearing mice.
    Jin Q, Zhou X, Niu X, Ping C, Dong X, Duan D, Wang R, Chen Y, Pan F, Yang F, Yang X, Zhang G, Wang R, Zhang S, Ren G.
    Colloids Surf B Biointerfaces; 2024 Sep 01; 241():113992. PubMed ID: 38833960
    [Abstract] [Full Text] [Related]

  • 12. [Physicochemical Property of iRGD Peptide Modified Doxorubicin Loaded Liposome and Its Effect on Cancer Cell Growth].
    Zhang ZQ, Zhong CL, Zhao X.
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2015 Nov 01; 46(6):837-41. PubMed ID: 26867317
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies.
    Zhang YF, Wang JC, Bian DY, Zhang X, Zhang Q.
    Eur J Pharm Biopharm; 2010 Mar 01; 74(3):467-73. PubMed ID: 20064608
    [Abstract] [Full Text] [Related]

  • 15. The co-delivery of a low-dose P-glycoprotein inhibitor with doxorubicin sterically stabilized liposomes against breast cancer with low P-glycoprotein expression.
    Gao W, Lin Z, Chen M, Yang X, Cui Z, Zhang X, Yuan L, Zhang Q.
    Int J Nanomedicine; 2014 Mar 01; 9():3425-37. PubMed ID: 25092974
    [Abstract] [Full Text] [Related]

  • 16. Coadministration of Oligomeric Hyaluronic Acid-Modified Liposomes with Tumor-Penetrating Peptide-iRGD Enhances the Antitumor Efficacy of Doxorubicin against Melanoma.
    Deng C, Zhang Q, Fu Y, Sun X, Gong T, Zhang Z.
    ACS Appl Mater Interfaces; 2017 Jan 18; 9(2):1280-1292. PubMed ID: 28009503
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The antitumor activity of tumor-homing peptide-modified thermosensitive liposomes containing doxorubicin on MCF-7/ADR: in vitro and in vivo.
    Wang C, Wang X, Zhong T, Zhao Y, Zhang WQ, Ren W, Huang D, Zhang S, Guo Y, Yao X, Tang YQ, Zhang X, Zhang Q.
    Int J Nanomedicine; 2015 Jan 18; 10():2229-48. PubMed ID: 25834435
    [Abstract] [Full Text] [Related]

  • 20. The prednisolone phosphate‑induced suppression of the angiogenic function of tumor‑associated macrophages enhances the antitumor effects of doxorubicin on B16.F10 murine melanoma cells in vitro.
    Licarete E, Rauca VF, Luput L, Patras L, Sesarman A, Banciu M.
    Oncol Rep; 2019 Dec 18; 42(6):2694-2705. PubMed ID: 31578578
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.